Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
The BBI Group developed, in collaboration with the Defence Science and Technology Laboratory, a rapid test for Ebola that is in the process of being verified to allow EUA submission. Using lateral flow technology, BBI’s assay will make testing simpler and quicker than assays that require technical infrastructure.
Cepheid unveiled the GeneXpert Omni, a portable molecular diagnostics system enabling access to accurate, fast, and potentially life-saving diagnosis of tuberculosis, HIV, and Ebola in even the most remote areas of the world.
Medical Electronic Systems released its new automated sperm quality analyzer, the SQA-Vision. Developed based on 10 years of market feedback, the SQA-Vision is positioned to augment Medical Electronic’s line of SQA-V and QwikCheck semen analyzers with a top-of-the-line solution.
The Diatron Group displayed its new walkaway clinical chemistry analyzer, the Pictus P500. This medium-throughput system (215 tests per hour on a typical sample mix) is ergonomically designed and user-friendly. The advanced, intuitive Windows-based software and smart architecture means the P500 offers many features on an accessible platform including uninterrupted workflow, enhanced walkaway operation, and remote-access diagnostics.
Festo displayed the EXCM mini H-gantry, its high-speed automated handling system for clinical laboratories. The planar surface gantry system is fast, accurate, modular, and flexible. This plug-and-play system can be used for dosing, barcode-based sample identification, liquid dispensing/pipetting with the addition of a Z-axis, and more. The desktop system moves vials on a planar X/Y axis with absolute positioning accuracy.
Nuclea Biotechnologies will begin offering more than 50 research-use-only mass spectrometry–based biomarker tests as part of its laboratory services. The tests detect and quantify protein biomarkers in human serum or plasma and are available to pharmaceutical companies for clinical trials, to researchers, and as companion diagnostics.
Swisslog Healthcare Solutions announced the launch of its Nexus Station. As the next generation of pneumatic tube stations, the Nexus Station provides quiet delivery of PTS carriers and improved carrier management through a carousel that handles both send and receive actions.
Diadexus and Mayo Clinic signed an agreement to collaborate in the areas of education, research, and innovation on the PLAC Test for Lp-PLA2 Activity. The FDA-cleared test is used to identify risk for coronary heart disease in patients with no history of cardiovascular events.
Beckman Coulter Diagnostics’ boothBeckman Coulter Diagnostics’ booth showcased its portfolio of high-productivity analytical and workflow systems. Solutions featured in the booth included the Power Express automation solution, the new DxH Connected Workcell, and IRIS International urinalysis solutions for automated urinalysis.
The Binding Site announced the formation of its new Immunologicals Group. Formerly known as OEM, this new team will have a broad remit to encompass the sales, marketing, and support of specialist antibodies, antigens, disease state sera, and services to IVD manufacturers, research scientists, and academic facilities.
